<DOC>
	<DOCNO>NCT01921387</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose radiolabeled monoclonal antibody give together combination chemotherapy stem cell transplant see well work treat patient high-risk lymphoid malignancy . Radiolabeled monoclonal antibody , yttrium Y 90 anti-CD45 monoclonal antibody BC8 , find cancer cell carry cancer-killing substance without harm normal cell . Giving chemotherapy stem transplant stop growth cancer cell stop divide kill . Stem cell collect patient 's blood return patient replace blood-forming cell destroy radiolabeled monoclonal antibody chemotherapy .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Combination Chemotherapy Before Stem Cell Transplant Treating Patients With High-Risk Lymphoid Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum-tolerated dose ( MTD ) 90Y-BC8-DOTA ( yttrium Y 90 anti-CD45 monoclonal antibody BC8 ) ( anti-cluster differentiation [ CD ] 45 ) deliver prior myeloablative carmustine , etoposide , cytarabine , melphalan ( BEAM ) chemotherapy autologous stem cell transplant ( ASCT ) patient high-risk B-non-Hodgkin lymphoma ( NHL ) , T-NHL , Hodgkin lymphoma ( HL ) . II . To evaluate efficacy 90Y-BC8-DOTA administer estimate MTD prior BEAM chemotherapy ASCT patient high-risk B-NHL , T-NHL , HL compare historical control treat BEAM alone . SECONDARY OBJECTIVES : I . To describe toxicity observe addition 90Y-BC8-DOTA BEAM . II . To optimize protein dose ( Ab ) deliver favorable biodistribution majority patient . III . To describe response rate overall survival patient high-risk B-NHL , T-NHL , HL follow administration 90Y-BC8-DOTA plus BEAM prior ASCT . IV . To describe impact rituximab concentration , B-cell depletion , disease burden CD45 target . V. To assess correlation lymphoma biomarkers outcomes . VI . To evaluate effect nodal-targeted irradiation 90Y-BC8-DOTA immune reconstitution follow ASCT . OUTLINE : This phase I , dose-escalation study yttrium Y 90 anti-CD45 monoclonal antibody BC8 follow phase II study . Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 intravenously ( IV ) day -14 . Patients also receive carmustine IV 3 hour day -7 , etoposide IV 2 hour twice daily ( BID ) day -6 -3 , cytarabine IV 4 hour BID day -6 -3 , melphalan IV 30 minute day -2 . Patients undergo autologous peripheral blood stem cell ( PBSC ) transplant day 0 . After completion study treatment , patient follow 3 , 6 , 12 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<criteria>Patients must histologically confirm diagnosis BNHL , TNHL , HL ; patient classical HL must document histologic demonstration CD45+ cell adjacent Reed Sternberg cell ; patient must receive least one prior standard systemic therapy document recurrent refractory disease ; patient mantle cell lymphoma ( MCL ) , TNHL , highrisk malignancy may enrolled/transplanted complete remission ( CR ) /first partial remission ( PR1 ) Creatinine &lt; 2.0 Bilirubin &lt; 1.5 mg/dL All patient eligible therapeutic study must minimum &gt; = 2 x10^6 CD34/kg autologous hematopoietic stem cell harvest cryopreserved Patients must expect survival &gt; 60 day must free major infection Circulating human antimouse antibody ( HAMA ) , determine infusion Systemic antilymphoma therapy give previous 30 day schedule therapy dose exception rituximab Inability understand give inform consent Lymphoma involve central nervous system Other serious medical condition consider represent contraindication ASCT ( e.g. , abnormally decreased cardiac ejection fraction , diffusion capacity carbon monoxide [ DLCO ] &lt; 50 % predict , etc . ) Known human immunodeficiency virus ( HIV ) seropositivity Pregnancy breast feed Prior autologous allogeneic bone marrow stem cell transplant Prior radiation therapy ( RT ) &gt; 20 gray ( Gy ) critical organ within 1 year enrollment Southwestern Oncology Group ( SWOG ) performance status &gt; = 2.0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>